Regeneron Pharmaceuticals IncREGN
▲ PositiveCapitalrelevance
Article states Regeneron is undervalued based on P/E ratio and valuation screens, implying upside potential.
Impact on stocks 1
Biotech & Genomic Medicine
Regeneron Pharmaceuticals IncRegeneron Pharmaceuticals stock has gained 20.2% over the past year, yet valuation checks still lean toward the shares looking inexpensive. The company trades on a price-to-earnings ratio of 15.0 times, below the biotech industry average of 17.3 times and a peer group average of 37.4 times. Simply Wall St's fair multiple suggests a P/E closer to 25.0 times, implying a sizeable gap to the current level. Regeneron screens as undervalued in all six areas assessed, pointing to the market price sitting below what these valuation tests suggest could be justified.
Regeneron Pharmaceuticals IncArticle states Regeneron is undervalued based on P/E ratio and valuation screens, implying upside potential.